DMARDs and Immunosuppressives Flashcards
What are the
(a) uses
(b) limitations
of NSAID tx for RA
NSAIDs for RA
(a) Uses = anti-inflammatory and analgesic, it will help w/ the pain and inflammation
(b) Not addressing the underlying autoimmunity
What is the gold standard DMARD drug?
Methotrexate = most efficacious
Efficacy
- mild-moderate = hydroxychloroquine
- moderate = sulfasalazine
- moderate-excellent = methotrexate
Toxicity of Hydroxychloroquine
Hydroxychloroquine = DMARD
Only mildly effective, but very well tolerated
-rare toxicity = retinal disease
Mechanism of hydroxychloroquine
-inhibits toll like receptors
Exact mechanism not known, but works far up in the line to prevent autoimmunity (before the disease gets fully going)
-alters antigen presentation and TLRs
Sulfasalazine toxicity
- GI intolerance
- liver toxicity
- marrow suppression
Indications for sulfasalazine
RA, psoriatic arthritis, IBD
Which DMARD is the most toxic? What should be monitored?
MTX (methotrexate) = most effective, most toxic
Monitoring necessary for
-liver and marrow function
Also can cause rheuamtoid nodules
Mechanism of methotrexate usage in cancer vs. RA
Cancer = very high dose MTX (comparatively): mechanism of MTX is to inhibit DNA synthesis by inhibiting folate synthesis
RA = lower doses, not used to inhibit folate (sometimes even give RA pts on MTX folate supplements)
- MTX promotes release of adenosine into the extracellular space
- Adenosine binds to receptor and generates anti-inflammatory effects inside the cell
What is the next step in therapy after trying MTX?
Multidrug therapy
-use a combo of the DMARDS (even all 3 at once) => superior/additive benefit
Metalloproteinase
(a) fxn
(b) what cells produce it
(c) release stimulated by what
Metalloproteinase
(a) enzyme that when released enzymatically degrades articular cartilage
(b) produced by synoviocytes
(c) stimulated by TNFalpha and IL-1
Infliximab
‘mab’ = monoclonal antibody
Infliximab = Remicade = partially humanized anti-TNF antibody
-deliver intravenously
Entanercept
‘cept’ = uses receptor
Entanercept = Enbrel = TNF-receptor fused to IgG Fc
-subQ injection
Adalimumab
Adalimumab = Humira = fully humalized anti-TNF anitbody
-subQ injection
Limitations of TNF blockers
Infliximab, Entanercept, Adalimumab
- All proteins => can’t be taken orally
- Large molecules => only work extracellularly
Response to TNF blockers
Great response, huge decrease in radiologic progression
-prevents erosion
Toxicity of TNF blockers
Pretty well tolerated (low toxicity) but MUST screen first for Tb
-TNF blockers increase risk of reactivation of latent Tb infection
Anakinra
Anakinra = IL-1Ra = IL-1 receptor antagonist
-endogenously produced IL-1 blocker
Compare efficacy of anakinra and infliximab
Anakinra (IL-1Ra) is much less efficacious then infliximab (anti-TNF antibody) in RA
-shows us that TNF is a much more potent disease/inflammatory mediator than IL-1 in rheumatoid arthritis
What is anakinra first line of therapy for?
Anakinra (IL-1 receptor antagonist) is extremely beneficial against inflammasome mediated rheumatic disease = gout!
Tocilizumab
Tocilizumab = Anti-IL-6 receptor antibody
- antibody against the receptor blocks access of IL-6 ligand
- Tocilizumab often used in combination w/ MTX in RA treatment
Name four biologic targets for RA treatment
4 things that are very involved in the pathophysiology of RA = good treatment targets
- cytokines (TNF, IL-1, IL-6)
- T-cells
- B-cells
- antigen presenting
Why would targeting T cells be effective against TA?
T-cells are crucial to accept antigen presentation and activate B cells to produce autoantibodies
Explain how Leflunomide targets T cells
Leflunomide = blocks T-cell proliferation by inhibiting pyrimidine synthesis
-targets T cells b/c they lack salvage pathways, specifically lacking pyrimidine (and purine) salvage pathways
What are the shared toxicities of Leflunomide and MTX
Leflunomide (block pyrimidine synthesis which targets T cells b/c they lack salvage pathways) and MTX
- hepatotoxicity
- teratogenicity